Last $2.09 USD
Change Today -0.06 / -2.79%
Volume 1.2M
ONTY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

oncothyreon inc (ONTY) Snapshot

Open
$2.13
Previous Close
$2.15
Day High
$2.15
Day Low
$2.07
52 Week High
03/13/14 - $4.08
52 Week Low
12/16/13 - $1.67
Market Cap
168.9M
Average Volume 10 Days
1.1M
EPS TTM
$-0.44
Shares Outstanding
80.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOTHYREON INC (ONTY)

oncothyreon inc (ONTY) Related Businessweek News

No Related Businessweek News Found

oncothyreon inc (ONTY) Details

Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

43 Employees
Last Reported Date: 03/13/14
Founded in 1985

oncothyreon inc (ONTY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $422.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $267.8K
Chief Operating Officer
Total Annual Compensation: $300.8K
Chief Medical Officer
Total Annual Compensation: $345.1K
Chief Scientific Officer
Total Annual Compensation: $262.7K
Compensation as of Fiscal Year 2013.

oncothyreon inc (ONTY) Key Developments

Oncothyreon Inc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Financial Guidance for the Full Year of 2014

Oncothyreon Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $6,032,000 or $0.09 per basic and diluted common share and loss from operations was $7,797,000 against net loss of $16,398,000 or $0.28 per basic and diluted common share and loss from operations was $18,047,000 a year ago. The decrease in loss from operations compared to the prior year periods was due to lower research and development expenses primarily attributable to a $10,000,000 upfront payment to Array BioPharma Inc. (Array) in June 2013. The decrease was partly offset by a slight increase in general and administrative expenses. The decrease in net loss compared to the prior year period was due to lower research and development expenses primarily attributable to an upfront payment of $10,000,000 to Array in June 2013, partially offset by a slight increase in general and administrative expenses. For the six months, the company reported net loss of $15,648,000 or $0.22 per basic and diluted common share and loss from operations was $14,957,000 against net loss of $24,686,000 or $0.43 per basic and diluted common share and loss from operations was $26,038,000 a year ago. The decrease in net loss compared to the prior year period was due to lower research and development expenses primarily attributable to the upfront payment of $10,000,000 to Array in June 2013, partially offset by $700,000 of non-cash expense from the change in fair value of warrant liability for the six months ended June 30, 2014 compared to $1,300,000 of non-cash income from the change in fair value of warrant liability for the six months ended June 30, 2013, and a slight increase in general and administrative expenses. The company believes the following financial guidance to be correct as of the date provided. The company is providing this guidance as a convenience to investors and assumes no obligation to update it. The company currently expects operating expenses in 2014 to be lower than in 2013, which included the one-time upfront payment to Array. The company currently expects cash used in operations in 2014 to be approximately $30 to $33 million, including expenses associated with the acquisition of Alpine Biosciences Inc. This guidance remains unchanged from that given in the prior quarter.

Jay Venkatesan to Join Oncothyreon Inc. as Executive Vice President and General Manager

Oncothyreon Inc. announced that it has acquired Alpine Biosciences Inc. Jay Venkatesan, M.D., Co-Founder and Chief Executive Officer of Alpine, will join Oncothyreon as Executive Vice President and General Manager with primary responsibility for the protocell development program.

Oncothyreon Inc, Q2 2014 Earnings Call, Aug 11, 2014

Oncothyreon Inc, Q2 2014 Earnings Call, Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTY:US $2.09 USD -0.06

ONTY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTY.
View Industry Companies
 

Industry Analysis

ONTY

Industry Average

Valuation ONTY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOTHYREON INC, please visit www.oncothyreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.